Sekeres MA - Search Results

1

Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP. Hosono N, et al. Among authors: sekeres ma. Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130. Oncotarget. 2017. PMID: 28031539 Free PMC article.

2

Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?

Sekeres MA, List A. Sekeres MA, et al. Curr Hematol Rep. 2005 May;4(3):182-5. Curr Hematol Rep. 2005. PMID: 15865869 Review.

3

Alternative treatments for myelodysplastic syndromes.

Sekeres M, List A. Sekeres M, et al. Semin Hematol. 2005 Jul;42(3 Suppl 2):S32-7. doi: 10.1053/j.seminhematol.2005.05.008. Semin Hematol. 2005. PMID: 16015503 Review.

4

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP. Szpurka H, et al. Among authors: sekeres ma. Blood. 2006 Oct 1;108(7):2173-81. doi: 10.1182/blood-2006-02-005751. Epub 2006 Jun 1. Blood. 2006. PMID: 16741247 Free PMC article.

5

Immunomodulation in myelodysplastic syndromes.

Sekeres MA, List A. Sekeres MA, et al. Best Pract Res Clin Haematol. 2006;19(4):757-67. doi: 10.1016/j.beha.2006.06.001. Best Pract Res Clin Haematol. 2006. PMID: 16997181 Review.

6

High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes.

O'Keefe CL, Tiu R, Gondek LP, Powers J, Theil KS, Kalaycio M, Lichtin A, Sekeres MA, Maciejewski JP. O'Keefe CL, et al. Among authors: sekeres ma. Exp Hematol. 2007 Feb;35(2):240-51. doi: 10.1016/j.exphem.2006.09.016. Exp Hematol. 2007. PMID: 17258073 Free PMC article.

7

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.

Sekeres MA, Fu AZ, Maciejewski JP, Golshayan AR, Kalaycio ME, Kattan MW. Sekeres MA, et al. Cancer. 2007 Mar 15;109(6):1125-32. doi: 10.1002/cncr.22497. Cancer. 2007. PMID: 17265521 Free article.

8

The incidence and impact of thrombocytopenia in myelodysplastic syndromes.

Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R, Leveque J. Kantarjian H, et al. Among authors: sekeres ma. Cancer. 2007 May 1;109(9):1705-14. doi: 10.1002/cncr.22602. Cancer. 2007. PMID: 17366593 Free article. Review.

9

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.

Golshayan AR, Jin T, Maciejewski J, Fu AZ, Bershadsky B, Kattan MW, Kalaycio ME, Sekeres MA. Golshayan AR, et al. Among authors: sekeres ma. Br J Haematol. 2007 Apr;137(2):125-32. doi: 10.1111/j.1365-2141.2007.06546.x. Br J Haematol. 2007. PMID: 17391492 Free article. Review.

10

Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts.

Nearman ZP, Szpurka H, Serio B, Warshawksy I, Theil K, Lichtin A, Sekeres MA, Maciejewski JP. Nearman ZP, et al. Among authors: sekeres ma. Am J Hematol. 2007 Dec;82(12):1076-9. doi: 10.1002/ajh.20995. Am J Hematol. 2007. PMID: 17654685 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

428 results

Search Page

Filters